Alvotech & Dr. Reddy's Partner on Keytruda Biosimilar

  Published 10 months ago

Alvotech and Dr. Reddy's are collaborating to develop, manufacture, and commercialize a biosimilar to Keytruda, a $29.5 billion cancer treatment. The partnership aims to accelerate development and expand global access.

  • Joint development and cost sharing.
  • Global commercialization rights for both.
  • Targets Keytruda’s $29.5B market.

You might like these

Ujjivan SFB Jumps on Buy Rating

HCLTech Appoints Global GCC Practice Head

BLS International Q1 Profit Jumps 49%

US-China Trade Tensions Flare Again

Gland Pharma Wins 180-Day US Exclusivity for GIAPREZA Generic

NMDC July Iron Ore Sales Up 13%

Global Science Race: US Funding Cuts Spur Talent Grab

News that matters the most ⚡